Novartis, Janssen, Merck (MSD outside the United States and Canada), Lilly, and Pfizer have joined with DrugDev in hosting a repository of specific investigator information as part of the Investigator Databank.
Novartis, Janssen, Merck (MSD outside the United States and Canada), Lilly, and Pfizer have joined with DrugDev in hosting a repository of specific investigator information as part of the Investigator Databank. In addition, investigators can now access the Investigator Databank through the launch of http://www.investigatordatabank.org. Through this website, investigators can securely log in, view and add to their information kept on file by the participating pharmaceutical companies or DrugDev.
The new website http://www.investigatordatabank.org enables the upload of standard essential documents such as CVs, GCP training certificates, and non-study specific site profile forms into a global repository, eliminating some of the repetitive, administrative tasks associated with study feasibility, site qualification, and site start-up.
With five member companies now on board, the Investigator Databank has grown to include nearly 180,000 investigators, 50,000 sites and 7,335 studies.
Read the full release here.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.